First Private Mission Readies for Launch to ISS

The International Space Station (ISS) photographed by Expedition 56 crew members from a Soyuz spacecraft after undocking, October 4, 2018. — Reuters
The International Space Station (ISS) photographed by Expedition 56 crew members from a Soyuz spacecraft after undocking, October 4, 2018. — Reuters
TT

First Private Mission Readies for Launch to ISS

The International Space Station (ISS) photographed by Expedition 56 crew members from a Soyuz spacecraft after undocking, October 4, 2018. — Reuters
The International Space Station (ISS) photographed by Expedition 56 crew members from a Soyuz spacecraft after undocking, October 4, 2018. — Reuters

The first fully private mission to the International Space Station is set to blast off Friday with a four-member crew from startup company Axiom Space.

The partnership has been hailed by NASA, which sees it as a key step in its goal to commercialize the region of space known as "low Earth orbit," leaving the agency to focus on more ambitious endeavors deeper into the cosmos, AFP said.

Takeoff is set for 11:17 am (1517 GMT) from the Kennedy Space Center in Florida on a SpaceX rocket.

Commanding the Axiom-1 mission will be former NASA astronaut Michael Lopez-Alegria, a dual citizen of the United States and Spain.

He is joined by three paying crewmates: American real estate investor Larry Connor, Canadian businessman Mark Pathy, and Israeli former fighter pilot and entrepreneur Eytan Stibbe.

The widely reported price for tickets -- which includes eight days on the outpost -- is $55 million.

But unlike the recent, attention-grabbing suborbital flights carried out by Blue Origin and Virgin Galactic, Axiom says its mission shouldn't be considered tourism.

On board the ISS, which orbits 250 miles (400 kilometers) above sea level, the quartet will carry out scientific research projects, including on aging in space, experiments with stem cells, and a technology demonstration of a self-assembling spacecraft.

"The distinction is that our guys aren't going up there and floating around for eight days taking pictures and looking out of the cupola," Derek Hassmann, operations director of Axiom Space, told reporters at a pre-launch briefing.

"I mean we have a very intensive and research-oriented timeline plan for them."

In addition, crewmember Stibbe plans to carry out a tribute to his friend Ilan Ramon, Israel's first astronaut, who died in the 2003 Space Shuttle Columbia disaster when the spaceship disintegrated upon reentry.

Surviving pages from Ramon's space diary, as well as mementos from his children, will be brought to the station by Stibbe.

The Axiom crew will live and work alongside the station's regular crew: currently three Americans and a German on the US side, and three Russians on the Russian side.

The company has partnered for a total of four missions with SpaceX, and NASA has already approved in principle the second, Ax-2.

Axiom sees the voyages as the first steps of a grander goal: to build its own private space station. The first module is due to launch in September 2024, president and CEO Michael Suffredini said.

The plan is for it to initially be attached to the ISS, before eventually flying autonomously when the latter retires and is deorbited sometime after 2030.



Blood Tests Allow 30-year Estimates of Women's Cardio Risks, New Study Says

A woman jogs in a park in Saint-Sebastien-sur-Loire near Nantes, France January 19, 2024. REUTERS/Stephane Mahe/File Photo Purchase Licensing Rights
A woman jogs in a park in Saint-Sebastien-sur-Loire near Nantes, France January 19, 2024. REUTERS/Stephane Mahe/File Photo Purchase Licensing Rights
TT

Blood Tests Allow 30-year Estimates of Women's Cardio Risks, New Study Says

A woman jogs in a park in Saint-Sebastien-sur-Loire near Nantes, France January 19, 2024. REUTERS/Stephane Mahe/File Photo Purchase Licensing Rights
A woman jogs in a park in Saint-Sebastien-sur-Loire near Nantes, France January 19, 2024. REUTERS/Stephane Mahe/File Photo Purchase Licensing Rights

Women’s heart disease risks and their need to start taking preventive medications should be evaluated when they are in their 30s rather than well after menopause as is now the practice, said researchers who published a study on Saturday.

Presenting the findings at the European Society of Cardiology annual meeting in London, they said the study showed for the first time that simple blood tests make it possible to estimate a woman’s risk of cardiovascular disease over the next three decades.

"This is good for patients first and foremost, but it is also important information for (manufacturers of) cholesterol lowering drugs, anti-inflammatory drugs, and lipoprotein(a)lowering drugs - the implications for therapy are broad," said study leader Dr. Paul Ridker of Brigham and Women’s Hospital in Boston, Reuters reported.

Current guidelines “suggest to physicians that women should generally not be considered for preventive therapies until their 60s and 70s. These new data... clearly demonstrate that our guidelines need to change,” Ridker said. “We must move beyond discussions of 5 or 10 year risk."

The 27,939 participants in the long-term Women’s Health Initiative study had blood tests between 1992 and 1995 for low density lipoprotein cholesterol (LDL-C or “bad cholesterol”), which are already a part of routine care.

They also had tests for high-sensitivity C-reactive protein (hsCRP) - a marker of blood vessel inflammation - and lipoprotein(a), a genetically determined type of fat.

Compared to risks in women with the lowest levels of each marker, risks for major cardiovascular events like heart attacks or strokes over the next 30 years were 36% higher in women with the highest levels of LDL-C, 70% higher in women with the highest levels of hsCRP, and 33% higher in those with the highest levels of lipoprotein(a).

Women in whom all three markers were in the highest range were 2.6 times more likely to have a major cardiovascular event and 3.7 times more likely to have a stroke over the next three decades, according to a report of the study in The New England Journal of Medicine published to coincide with the presentation at the meeting.

“The three biomarkers are fully independent of each other and tell us about different biologic issues each individual woman faces,” Ridker said.

“The therapies we might use in response to an elevation in each biomarker are markedly different, and physicians can now specifically target the individual person’s biologic problem.”

While drugs that lower LDL-C and hsCRP are widely available - including statins and certain pills for high blood pressure and heart failure - drugs that reduce lipoprotein(a) levels are still in development by companies, including Novartis , Amgen , Eli Lilly and London-based Silence Therapeutics.

In some cases, lifestyle changes such as exercising and quitting smoking can be helpful.

Most of the women in the study were white Americans, but the findings would likely “have even greater impact among Black and Hispanic women for whom there is even a higher prevalence of undetected and untreated inflammation,” Ridker said.

“This is a global problem,” he added. “We need universal screening for hsCRP ... and for lipoprotein(a), just as we already have universal screening for cholesterol.”